OncoCyte president and CEO Ron (Ronnie) Andrews discussed the company's recent acquisitions and expansion of its diagnostics menu with GEN Edge . . .
- Cancer
- Drug Discovery
- Breast Cancer
- Lung Cancer
- Therapeutics
- Immuno-oncology
- Immunotherapies
- GEN Edge
- Molecular Diagnostics/In vitro Diagnostics
- Reimbursement
OncoCyte Launches NSCLC Stratification Test, Looks beyond Lung Cancer
CEO Ron (Ronnie) Andrews discusses acquisitions, diagnostics menu expansion with GEN Edge
Three days before the DetermaRx U.S. launch announcement on January 10, OncoCyte signaled its intent to broaden its lung cancer test menu when it agreed to acquire privately held Insight Genetics for approximately $12 million. [Source: Source: Kateryna Kon/Science Photo Library/Getty Images]
![Research appearing in The Lancet Oncology suggests that those receiving one year of treatment have a 1.2% risk. [© David G - Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/June14_4377221_PillsOnCardiogram_ARBsCauseCancer_Omics1442022161-100x70.jpg "Scientists Find Link Between ARB Therapy and Cancer")